Can steroids save lives in severe pneumonia? new trial aims to find out
NCT ID NCT07152587
First seen Jun 24, 2026 · Last updated Jun 26, 2026 · Updated 1 time
Summary
This trial tests whether low or moderate doses of the steroid methylprednisolone can reduce deaths in patients with severe community-acquired pneumonia. It will enroll 1500 ICU patients with pneumonia caused by adenovirus or Pneumocystis jirovecii. The study uses an adaptive design to assign more patients to the better-performing dose.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Methylprednisolone (a steroid)
- What this could lead to
- If successful, this could identify the best steroid dose to reduce deaths from severe pneumonia caused by certain viruses or fungi.
- What could go wrong
- This is an early-stage trial with only 1500 participants, and steroids can have serious side effects like infections or bleeding. The results may not apply to all pneumonia patients.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PNEUMOCYSTIS JIROVECII-ASSOCIATED SEVERE COMMUNITY-ACQUIRED PNEUMONIA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.